Personalis, Inc. 8-K

What Happened Personalis, Inc. announced via Form 8‑K that on May 12, 2026 the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program expanded Medicare coverage for the company's ultrasensitive NeXT Personal® test to include immunotherapy monitoring for patients with late‑stage solid tumors. The Form 8‑K was filed May 13, 2026 and signed by Aaron Tachibana, Chief Financial Officer and Chief Operating Officer.

Key Details

• CMS Molecular Diagnostics Program expanded Medicare coverage effective May 12, 2026.
• Coverage specifically adds immunotherapy monitoring for patients with late‑stage solid tumors using the ultrasensitive NeXT Personal® test.
• Personalis disclosed the change in an Item 8.01 ("Other Events") Form 8‑K filed on May 13, 2026.
• Filing signed by Aaron Tachibana (CFO & COO).

Why It Matters Medicare coverage for a diagnostic test affects patient access and reimbursement pathways; this decision removes a barrier for Medicare beneficiaries to receive immunotherapy monitoring with Personalis’s NeXT Personal test. For investors, expanded Medicare coverage is a key commercial milestone that can influence test utilization and reimbursement trends—factors that may impact future revenue and adoption in the late‑stage solid tumor market.